Background. Leprosy or Hansen's disease is a chronic mycobacterial infection caused by mycobacterium leprae. Reactions in Leprosy represent an acute inflammataory response during the natural chronic course of infection. Type 2 lepra reaction is a Th2-mediated type III hypersensitivity reaction in leprosy, with a characteristic cutaneous manifestation in the form of erythema nodosum leprosum (ENL). This presentation describes unusual presentations of Type 2 lepra reaction in five patients.
Methods. Patient data and dermatological findings were analyzed in three men and two women diagnosed with Hansen's disease (Leprosy).
Results. Findings included multiple tender, polycyclic, necrotic lesions distributed over the face in one patient, and painful, fluid-filled lesions on both arms and lower limbs in another. The third patient showed erythematous, tender nodules, bullae, and necrotic ulcers over the back and upper and lower limbs. The fourth showed erythematous tender nodules over the face, neck, back, and extremities, predominantly in sun-exposed areas. The fifth revealed multiple erythematous, severely tender nodules and urticarial plaques mimicking those of Sweet's syndrome. Diagnosis of borderline or lepromatous leprosy with atypical Type 2 reaction were made in all cases.
Conclusion. Type 2 lepra reactions are antigen antibody-mediated immune complex reactions that present with constitutional symptoms and ENL characterized by tender, erythematous, evanescent nodules mainly on the face, arms, and legs. Over 50% of lepromatous leprosy patients and 25% of borderline lepromatous leprosy patients experienced type 2 lepra reactions prior to the advent of multi-drug therapy. Thalidomide is the drug of choice for severe atypical lepra reactions because of its anti-tumor necrosis factor-α action. Awareness of these atypical variants and prompt diagnosis and treatment are essential to prevent mortality and morbidity in potentially treatable patients.
Disclosures. All authors: No reported disclosures. Background. Texas Center for Infectious Disease is a hospital that specializes in the treatment of tuberculosis (TB). Fluoroquinolones (FQ) play a vital role in the management of TB. FQ are used in patients with drug-resistant TB, intolerance to first line TB medications, extensive disease, elevated liver function tests (LFT) or a combination of these factors. Reasons for switching from one FQ to another, as well as duration of treatment prior to switching were retrospectively reviewed.
Patterns of Fluoroquinolone Prescribing at a Tuberculosis Hospital
Methods. All orders for FQ from January 1, 2012 to December 31, 2016 were reviewed. Data collected included FQ start/stop dates and indication for use. If a switch was made from one FQ to another, the reason for the switch and the duration of treatment prior to switching was collected.
Results. 195 patients had orders for FQ. Indications for use included drug-resistant TB 72 (34.8%), elevated LFT 70 (33.8%), extensive disease 27 (13%), isoniazid (INH) or rifampin (RIF) intolerance 22 (10.6%), treatment failure 7 (3.4%), other reasons 5 (2.4%), and drug reaction with eosinophilia and systemic symptoms (DRESS) 4 (1.9%). There were 12 patients with more than one indication for FQ use. For those patients with drug-resistant TB, 42 (58.3%) had multidrug-resistant TB, 19 (26.4%) INH-resistant TB, 5 (6.9%) pre XDR-TB, 4 (5.6%) RIF-resistant TB, and 2 (2.8%) extremely drug-resistant TB (XDR-TB). Levofloxacin (LVF) was used as the initial FQ in 96 (49.2%) and moxifloxacin (MOX) in 99 (50.8%) patients. There were 69 switches in 51 patients from one FQ to another, 44(63.8%) from LVF to MOX and 25 (36.2%) from MOX to LVF. The most common reason for switching from LVF to MOX was arthralgias in 28 (63.6%) and from MOX to LVF were elevated LFT in 8 (32%) and gastrointestinal intolerance in 7 (28%). The mean duration of treatment prior to switch from LVF to MOX was 70.3 days and from MOX to LVF was 61.3 days.
Conclusion. The most common reasons for FQ use were drug-resistant TB and elevated LFT. There was no significant difference between the frequency of use of LVF and MOX as the initial FQ. More patients were switched from LVF to MOX. The most common indication for switching from LVF to MOX was arthralgias and from MOX to LVF was elevated LFT. The time until development of adverse reactions was longer for LVF than for MOX.
Disclosures. All authors: No reported disclosures. Background. Mycobacterium genavense can cause serious disease in the immunocompromised. We report our experience with this uncommon infection. (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) .
Disseminated

Methods. Retrospective review of M. genavense infection at Mayo Clinic
Results. Three patients were diagnosed with M. genavense from 2010 to 2017 (Table 1) . Lymph node biopsy noted non-necrotizing granulomatous inflammation with AFB in 2 patients. Delayed growth in culture was noted after at least 6 weeks incubation. All patients were started on mycobacterial therapy; no isolate grew sufficiently for drug susceptibility testing.
Conclusion.
M. genavense is an environmental mycobacteria, it rarely causes infection in non-HIV hosts. Our cases involved advanced HIV, solid organ transplant and idiopathic CD4 lymphopenia. Presentation with GI and systemic symptoms is common, pulmonary and cutaneous less so. Growth in culture requires prolonged incubation (8-12 weeks) in broth media with Mycobactin J supplementation. Positive pathological examination for AFB organisms, negative probes for MTB or MAC combined with persistently negative cultures, should raise the suspicion for this organism in the right clinical setting. It is generally susceptible to rifamycins, fluoroquinolones and macrolides; resistant to isoniazid and sometimes pyrazinamide. Immunosuppression should be reduced if possible to speed recovery. Duration of therapy is usually at least 12 months for disseminated disease, depending on response and immunosuppression. 
